Strategic Health Policy Intelligence on China’s Evolving Coverage and Financing Architecture
Interpreting cross-layer regulatory signals and their commercial and strategic consequences.
Engagement Paths
Access360
Ongoing strategic intelligence platform
Strategy Session
High-density executive alignment engagement
Masterclass
Strategic primer on China’s multi-layer system
Selected Strategic Analyses
A curated selection of recent policy intelligence briefings. The full archive reflects ongoing structural shifts across China’s multi-layer coverage system.
From Reference Tool to Operating Model: A Roadmap for China’s C-List
A strategic roadmap outlining how China’s Commercial Innovative Drug List can evolve from a formulary reference into a coordinated operating model across financing layers.
Policy Briefing | January 2026
China’s Biosimilar VBP: Emerging Rules, Pricing Dynamics, and What Early Signals Suggest
A premier interpretive briefing on China’s biosimilar volume-based procurement (VBP)—exploring emerging rules, pricing dynamics, and early signals of downstream commercial impact.
Policy Briefing | December 2025
NFRAs’ Guiding Opinions: What They Mean for China’s Multi-Level Coverage Framework
An interpretive briefing on the NFRAs’ Guiding Opinions and their implications for China’s multi-layer coverage framework and financing dynamics.
Policy Briefing | November 2025
NHSA Strengthens Control Over Outpatient Spending
Effectively navigating these regulatory changes will have significant and lasting implications for drug manufacturers, particularly in shaping their pricing strategies, reimbursement models, and distribution channel approaches in China.
Policy Briefing | December 2024
Fair Pricing of Pharmaceuticals: Insights into China’s NRDL Negotiation
An open access analysis of how China’s NRDL negotiation is evolving from cost containment toward value-based resource allocation—examining VBP savings, BMI fund efficiency, renewal dynamics, and product-level pricing thresholds.
Policy Briefing | January 2024
Institutional access available for enterprise teams.
Discuss Enterprise Access.